Friedlander ML - Search Results

1

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.

Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P. Friedlander ML, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S78-82. doi: 10.1097/IGC.0000000000000239. Int J Gynecol Cancer. 2014. PMID: 25341585 Review.

2

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B. Amant F, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S67-72. doi: 10.1097/IGC.0000000000000205. Int J Gynecol Cancer. 2014. PMID: 25033257 Review.

3

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.

Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Hasegawa K, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5. doi: 10.1097/IGC.0000000000000297. Int J Gynecol Cancer. 2014. PMID: 25341588 Review.

4

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I. Reed NS, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41. doi: 10.1097/IGC.0000000000000265. Int J Gynecol Cancer. 2014. PMID: 25341578 Review.

5

Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.

Ledermann JA, Luvero D, Shafer A, O'Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J. Ledermann JA, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9. doi: 10.1097/IGC.0000000000000296. Int J Gynecol Cancer. 2014. PMID: 25341574 Review.

6

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.

Reed NS, Pautier P, Åvall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I. Reed NS, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S30-4. doi: 10.1097/IGC.0000000000000293. Int J Gynecol Cancer. 2014. PMID: 25341577 Review.

7

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.

Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ. Brown J, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223. Int J Gynecol Cancer. 2014. PMID: 25341580 Review.

8

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.

Joly F, Hilpert F, Okamoto A, Stuart G, Ochiai K, Friedlander M; of the participants of the 5th Ovarian Cancer Consensus Conference. Joly F, et al. Eur J Cancer. 2017 Jun;78:133-138. doi: 10.1016/j.ejca.2017.03.019. Epub 2017 Apr 25. Eur J Cancer. 2017. PMID: 28448857

9

Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.

Friedlander ML, Hedley DW, Swanson C, Russell P. Friedlander ML, et al. J Clin Oncol. 1988 Feb;6(2):282-90. doi: 10.1200/JCO.1988.6.2.282. J Clin Oncol. 1988. PMID: 3276825 Clinical Trial.

10

Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.

Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M; Gynecologic Cancer InterGroup (GCIG) symptom benefit committee. Kurtz JE, et al. Gynecol Oncol. 2021 May;161(2):502-507. doi: 10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19. Gynecol Oncol. 2021. PMID: 33612336 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page